Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Bern-Thomas Nyang'wa"'
Autor:
Catherine Berry, Philipp du Cros, Katherine Fielding, Suzanne Gajewski, Emil Kazounis, Timothy D. McHugh, Corinne Merle, Ilaria Motta, David A. J. Moore, Bern-Thomas Nyang’wa
Publikováno v:
Trials, Vol 23, Iss 1, Pp 1-16 (2022)
Abstract Background Globally rifampicin-resistant tuberculosis disease affects around 460,000 people each year. Currently recommended regimens are 9–24 months duration, have poor efficacy and carry significant toxicity. A shorter, less toxic and mo
Externí odkaz:
https://doaj.org/article/18cf0f1b88e446ff9f4a31b475111440
Autor:
Alexandra Wharton-Smith, Shona Horter, Emma Douch, Nell Gray, Nicola James, Bern-Thomas Nyang’wa, Jatinder Singh, Parpieva Nargiza Nusratovna, Zinaida Tigay, Emil Kazounis, Gulayim Allanazarova, Beverley Stringer
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-14 (2021)
Abstract Background Addressing the global burden of multidrug-resistant tuberculosis (MDR-TB) requires identification of shorter, less toxic treatment regimens. Médecins Sans Frontières (MSF) is currently conducting a phase II/III randomised contro
Externí odkaz:
https://doaj.org/article/e2fede73cd4149599b0eaf002feba403
Autor:
Sedona Sweeney, Catherine Berry, Emil Kazounis, Ilaria Motta, Anna Vassall, Matthew Dodd, Katherine Fielding, Bern-Thomas Nyang'wa
Publikováno v:
PLOS Global Public Health, Vol 2, Iss 12, p e0001337 (2022)
Current options for treating tuberculosis (TB) that is resistant to rifampicin (RR-TB) are few, and regimens are often long and poorly tolerated. Following recent evidence from the TB-PRACTECAL trial countries are considering programmatic uptake of 6
Externí odkaz:
https://doaj.org/article/53515999631e4a4f938642a06624c9fb
Autor:
Philipp du Cros, Atadjan Khamraev, Zinaida Tigay, Tleubergen Abdrasuliev, Jane Greig, Graham Cooke, Krzysztof Herboczek, Tanya Pylypenko, Catherine Berry, Amrita Ronnachit, David Lister, Sebastian Dietrich, Cono Ariti, Khasan Safaev, Bern-Thomas Nyang'wa, Nargiza Parpieva, Mirzagalib Tillashaikhov, Jay Achar
Publikováno v:
ERJ Open Research, Vol 7, Iss 1 (2021)
Background In 2016, World Health Organization guidelines conditionally recommended standardised shorter 9–12-month regimens for multidrug-resistant (MDR) tuberculosis (TB) treatment. We conducted a prospective study of a shorter standardised MDR-TB
Externí odkaz:
https://doaj.org/article/3e70b0468eba4a098cf9018347bf8949
Autor:
Gabriela Gomez, Sedona Sweeney, Nichola Kitson, Animesh Sinha, Natalia Yatskevich, Suzanne Staples, Ronelle Moodliar, Sharon Motlhako, Matshepo Maloma, Mohammed Rassool, Nosipho Ngubane, Ella Ndlovu, Bern-Thomas Nyang'wa
Publikováno v:
BMJ Open, Vol 10, Iss 10 (2020)
Introduction Current treatment regimens for multidrug-resistant tuberculosis (MDR-TB) are long, poorly tolerated and have poor outcomes. Furthermore, the costs of treating MDR-TB are much greater than those for treating drug-susceptible TB, both for
Externí odkaz:
https://doaj.org/article/39253a28127143758f1a1146774445bd
Autor:
Grania Brigden, Bern-Thomas Nyang'wa, Philipp du Cros, Francis Varaine, Jennifer Hughes, Michael Rich, C Robert Horsburgh Jr, Carole D Mitnick, Eric Nuermberger, Helen McIlleron, Patrick PJ Phillips, Manica Balasegaram
Publikováno v:
Bulletin of the World Health Organization, Vol 92, Iss 1, Pp 68-74 (2014)
Fewer than 20% of patients with multidrug-resistant (MDR) tuberculosis are receiving treatment and there is an urgent need to scale up treatment programmes. One of the biggest barriers to scale-up is the treatment regimen, which is lengthy, complex,
Externí odkaz:
https://doaj.org/article/3a141876b7684af6b2d26b55feec2b66
Autor:
Lenka Benova, Katherine Fielding, Jane Greig, Bern-Thomas Nyang'wa, Esther Carrillo Casas, Marcio Silveira da Fonseca, Philipp du Cros
Publikováno v:
PLoS ONE, Vol 7, Iss 4, p e35948 (2012)
The HIV epidemic has increased the proportion of patients with smear-negative and extrapulmonary tuberculosis (TB) diagnoses, with related higher rates of poor TB treatment outcomes. Unlike in smear-positive pulmonary TB, no interim markers of TB tre
Externí odkaz:
https://doaj.org/article/6f445829e8c24d9cbf9d86c10b7ff8b0
Publikováno v:
Bulletin of the World Health Organization, Vol 89, Iss 12, Pp 855-855 (2011)
Externí odkaz:
https://doaj.org/article/1163d5db5ad24f1893c32f1b3a7a4bd0
Publikováno v:
Bulletin of the World Health Organization, Vol 89, Iss 12, Pp 855-855
Externí odkaz:
https://doaj.org/article/08d73c2b10eb4135a30a3d98c71e941b
Autor:
Bern-Thomas, Nyang'wa, Catherine, Berry, Emil, Kazounis, Ilaria, Motta, Nargiza, Parpieva, Zinaida, Tigay, Varvara, Solodovnikova, Irina, Liverko, Ronelle, Moodliar, Matthew, Dodd, Nosipho, Ngubane, Mohammed, Rassool, Timothy D, McHugh, Melvin, Spigelman, David A J, Moore, Koert, Ritmeijer, Philipp, du Cros, Katherine, Fielding, Emma, Veitch
Publikováno v:
The New England journal of medicine. 387(25)
In patients with rifampin-resistant tuberculosis, all-oral treatment regimens that are more effective, shorter, and have a more acceptable side-effect profile than current regimens are needed.We conducted an open-label, phase 2-3, multicenter, random
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70a074020eb2011fea1bcf61c6576f78
https://pubmed.ncbi.nlm.nih.gov/36546625
https://pubmed.ncbi.nlm.nih.gov/36546625